Table 1.
Characteristics of patients deceased during COVID-19 epidemic
| Recipients |
Pa | Pb | Candidates |
Pc | Pd | Pe | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Alive on June 1 | Death from other causes | Death due to COVID-19 | Alive on June 1 | Death from other causes | Death due to COVID-19 | ||||||
| N | 42469 | 153 | 122 | 16,042 | 84 | 60 | 0.60 | ||||
| Male | 26,255 (61.8) | 105 (68.6) | 71 (58.2) | 0.08 | 0.41 | 9993 (62.3) | 59 (70.2) | 43 (71.7) | 0.13 | 0.13 | 0.08 |
| Age, yr | 56.9 ± 15 | 70 ± 10.5 | 66.5 ± 12.1 | <0.01 | <0.01 | 57.5 ± 13.9 | 63 ± 11.4 | 62.7 ± 10.5 | <0.01 | <0.01 | 0.04 |
| Cardiovascular disease | 3563 (13.4) | 26 (29.9) | 35 (33) | <0.01 | <0.01 | 2832 (18.7) | 25 (32.9) | 10 (17.5) | <0.01 | 0.82 | 0.04 |
| Diabetes | 5352 (18.9) | 26 (26) | 51 (46.8) | 0.07 | <0.01 | 4674 (30.1) | 42 (53.2) | 29 (49.2) | <0.01 | <0.01 | 0.77 |
| BMI, kg/m2 | 25.8 ± 5.2 | 25.5 ± 5.2 | 28 ± 5.2 | 0.5 | <0.01 | 26.2 ± 5.3 | 25.7 ± 5.8 | 28.4 ± 4.8 | 0.41 | <0.01 | 0.63 |
| Blood group | 0.16 | 0.24 | 0.39 | 0.5 | 0.27 | ||||||
| A | 18,423 (43.4) | 69 (45.1) | 47 (38.5) | 5308 (33.1) | 21 (25) | 15 (25) | |||||
| B | 1874 (4.4) | 10 (6.5) | 6 (4.9) | 537 (3.3) | 2 (2.4) | 2 (3.3) | |||||
| AB | 4599 (10.8) | 9 (5.9) | 20 (16.4) | 2369 (14.8) | 15 (17.9) | 12 (20) | |||||
| O | 17,555 (41.4) | 65 (42.5) | 49 (40.2) | 7828 (48.8) | 46 (54.8) | 31 (51.7) | |||||
| Cause of ESRD | 0.02 | <0.01 | <0.01 | <0.01 | 0.23 | ||||||
| Diabetes | 3403 (8) | 16 (10.5) | 27 (22.1) | 2641 (16.5) | 28 (33.3) | 21 (35) | |||||
| Glomerulonephritis | 10,738 (25.3) | 36 (23.5) | 17 (13.9) | 3151 (19.6) | 12 (14.3) | 9 (15) | |||||
| Nephroangiosclerosis | 2654 (6.2) | 19 (12.4) | 15 (12.3) | 1917 (12) | 9 (10.7) | 10 (16.7) | |||||
| Other | 11,201 (26.4) | 38 (24.8) | 37 (30.3) | 4207 (26.2) | 24 (28.6) | 12 (20) | |||||
| Polycystic kidney disease | 6860 (16.2) | 26 (17) | 18 (14.8) | 1952 (12.2) | 3 (3.6) | 4 (6.7) | |||||
| Tubulointerstitial nephritis | 7610 (17.9) | 18 (11.8) | 8 (6.6) | 2172 (13.5) | 8 (9.5) | 4 (6.7) | |||||
| Previous transplantation | 5538 (13) | 15 (9.8) | 14 (11.5) | 0.24 | 0.61 | 3423 (21.3) | 25 (29.8) | 14 (23.3) | 0.06 | 0.71 | 0.04 |
| Time since transplantation | |||||||||||
| Duration, mo | 114.2 ± 95.7 | 121.8 ± 94 | 99.5 ± 83.9 | 0.32 | 0.09 | ||||||
| ≤1 yr | 3404 (8) | 9 (5.9) | 16 (13.1) | 0.33 | 0.04 | ||||||
| Last eGFR MDRD, ml/min | 52.5 ± 22.7 | 39.8 ± 21 | 36.1 ± 19.9 | <0.01 | <0.01 | ||||||
| Time on dialysis, mo | 34.8 ± 46.7 | 39.8 ± 52.7 | 53 ± 43.6 | 0.25 | <0.01 | 40.4 ± 54.2 | 63.3 ± 60.1 | 42.2 ± 45.9 | <0.01 | 0.8 | 0.13 |
BMI, body mass index; COVID-19, coronavirus disease 2019; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; MDRD, Modification of Diet in Renal Disease.
The P values are for the following comparisons: arecipients alive vs. recipients deceased from other cause; brecipients alive vs. recipients deceased from COVID-19; ccandidates alive vs. candidates deceased from other causes; dcandidates alive vs. candidates deceased from COVID-19; edeaths from COVID-19 recipients vs. candidates.
Values are n (%) or mean (± SD), unless otherwise indicated.